Two-dimensional nano-label for CD46 detection as well as preparation method and application of two-dimensional nano-label
MoS2@AuNSs Raman-enhanced two-dimensional nanolabels were prepared by PEI self-assembly method, combined with immunochromatography technology, and the problem of equipment dependence and low sensitivity of CD46 detection in the existing technology was solved, and high sensitivity CD46 detection was achieved, which is of great importance. The clinical application of colorectal cancer liver metastasis monitoring and prognosis evaluation.
Patent Information
- Application Number
- CN202411063686.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art methods for CD46 detection rely on large-scale equipment, and the detection process is cumbersome and expensive, limiting its application in large-scale clinical screening and community health services. Traditional spherical Raman enhancement labels have low sensitivity and are difficult to achieve high sensitivity. quantitative detection.
MoS2@AuNSs Raman-enhanced two-dimensional nanolabels were prepared by PEI self-assembly method, and the high-performance SERS immune labels were formed for CD46 detection through ultrasound reaction and antibody coupling. Combined with immunochromatography technology, rapid and high-sensitivity detection was achieved. .
It realizes high sensitivity detection of CD46, improves detection sensitivity by at least 1000 times, simplifies the detection process, reduces equipment costs, has a wide range of application prospects in the fields of biochemical detection and rapid diagnosis, and has important clinical significance for liver metastasis of colorectal cancer. Monitoring and prognostic evaluation.
Smart Images

Figure CN118962113A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of novel nanomaterials, and in particular to a two-dimensional nano-label for CD46 detection and a preparation method and application thereof. Background Art
[0002] Colorectal cancer has become a clinically challenging disease with high morbidity and mortality, and has attracted much attention due to its severe tendency to metastasize and relapse. Liver metastasis is the main cause of colorectal cancer (CRC)-related death, and 1 / 4 of colorectal cancer patients have liver metastasis at the time of initial diagnosis. Although metastatic colorectal cancer has improved significantly, the long-term prognosis remains poor. In this study, the research team used protein profiling to screen out the significantly highly expressed protein CD46 in the tumor tissues of patients with colorectal cancer and liver metastasis. Combined with tissue microarray (TMA) containing ten-year follow-up data of 1,078 colorectal cancer patients and single-cell flow cytometry of colorectal cancer and adjacent tissues of 152 newly enrolled colorectal cancer patients, it was confirmed that increased expression of CD46 protein significantly increased the risk of liver metastasis and death in cancer patients. Therefore, CD46 can be used as a new marker for the detection of colorectal cancer liver metastasis. The detection results of molecular markers for the prediction of efficacy and prognosis evaluation of colorectal cancer are very important for the clinical formulation of correct treatment plans.
[0003] In recent years, highly sensitive MSD (Meson Scale Discovery) electrochemiluminescence technology and surface plasmon resonance sensors (SPR) have been applied to the detection of tumor marker-related proteins. The detection sensitivity based on SPR or electrical signals can reach 0.1pg / mL. However, these detection methods rely on large equipment and require samples to undergo cumbersome preliminary processing. The detection process usually takes more than 5 hours. Due to the high cost of equipment, only a few research institutions currently have such facilities, which limits their widespread application in large-scale clinical screening and community health service centers. Rapid and accurate detection of CD46 is of vital importance for the formulation of appropriate treatment and prognosis strategies.
[0004] SERS immunochromatographic detection is an immunoanalysis technology that combines SERS with labeled immunotechnology, using the high sensitivity and spectral characteristic peaks of SERS and the specific binding reaction of antibodies and antigens. The combination of SERS labeling detection technology and immunochromatographic detection technology has become a hot topic in related fields in recent years. However, the immunochromatographic technology of traditional spherical Raman enhanced labels relying on gold / silver colloids as the substrate has the defects of low detection sensitivity, poor binding ability with the target, and only qualitative or semi-quantitative detection ability. Two-dimensional nanomaterials have good stability, strong Raman enhancement performance, good biocompatibility, large specific surface area, and are easier to capture and detect targets. They can replace traditional gold / silver colloid SERS labels as two-dimensional SERS labels for immunochromatographic detection, and the detection sensitivity can be increased by at least 1000 times compared with ordinary ELISA. Therefore, it is crucial to develop new SERS labels for direct detection of CD46. Summary of the invention
[0005] The purpose of the present invention is to provide a two-dimensional nano-label for CD46 detection and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art.
[0006] To achieve the above object, the present invention provides the following solutions:
[0007] One of the technical solutions of the present invention is a method for preparing a two-dimensional nano-label for CD46 detection, comprising the following steps:
[0008] (1) adding MoS2 nanosheets to PEI solution and ultrasonicating to obtain MoS2@PEI particles;
[0009] (2) Gold nanostars were prepared using colloidal gold nanoparticles as seeds and bovine serum albumin as an inducer;
[0010] (3) mixing the MoS2@PEI particles and the gold nanostars, performing ultrasonic reaction, and centrifuging to obtain MoS2@AuNSs nanosheets;
[0011] (4) The MoS2@AuNSs nanosheet is reacted with 5,5'-dithiobis(2-nitrobenzoic acid) under ultrasonic conditions, and then activated in a carbodiimide solution and an N-hydroxysuccinimide solution, and coupled with a CD-46 antibody to obtain the two-dimensional nanotag.
[0012] The second technical solution of the present invention is a two-dimensional nano-tag prepared by the preparation method.
[0013] The third technical solution of the present invention is the use of the two-dimensional nano-label in the preparation of products for detecting CD46.
[0014] A fourth technical solution of the present invention is a kit or test strip for detecting CD46, comprising the two-dimensional nano-label.
[0015] A fifth technical solution of the present invention is the use of the two-dimensional nanolabel in the preparation of products for detecting colorectal cancer liver metastasis.
[0016] Based on the above technical solution, the present invention has the following technical effects:
[0017] (1) The present invention proposes to use PEI self-assembly method to prepare MoS2@AuNSs Raman enhanced two-dimensional nanostructures. The preparation method is simple, mature, and has good repeatability, and can be mass-produced.
[0018] (2) The MoS2@AuNSs Raman-enhanced two-dimensional nanotag proposed in the present invention has broad application prospects, including biochemical detection, biological analysis, rapid diagnosis and other fields. The MoS2@AuNSs Raman-enhanced two-dimensional nanotag can be used as a high-performance SERS immunolabel for rapid capture and detection of targets in the blood.
[0019] (3) The MoS2@AuNSs two-dimensional nanotag has the advantage of a large specific surface area and can bind to a large amount of target protein, which is more conducive to improving diagnostic sensitivity.
[0020] (4) The target detected by the present invention is CD46, which can be used as a new marker for monitoring liver metastasis of colorectal cancer. As a new tumor metastasis monitoring marker, the immune detection system of the present invention has important clinical significance for the metastasis monitoring and prognosis evaluation of colorectal cancer.
[0021] In summary, the MoS2@AuNSs Raman-enhanced two-dimensional nanotag of the present invention has a simple, efficient and repeatable preparation route. The prepared MoS2@AuNSs Raman-enhanced two-dimensional nanotag has the properties of monodispersity, large specific surface area and non-oxidation, and the particle size is uniform and adjustable. It is of great clinical significance for the detection of blood samples, especially for the detection of CD46 requiring a highly sensitive SERS immunochromatography system, for the metastasis monitoring and prognosis evaluation of colorectal cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0023] Figure 1 Schematic diagram of the preparation method of the MoS2@AuNSs Raman enhanced two-dimensional nano-label of the present invention;
[0024] Figure 2 The transmission electron microscopy (TEM) characterization results of the MoS2@AuNSs Raman-enhanced two-dimensional nanotag preparation process in Example 1 of the present invention, wherein a is MoS2 and b is MoS2@AuNSs;
[0025] Figure 3 The Raman signal characterization of the MoS2@AuNSs Raman enhanced nano-tag of Example 1 of the present invention;
[0026] Figure 4 This is an experimental flow chart of the MoS2@AuNSs Raman-enhanced two-dimensional nano-label as a high-performance SERS label combined with an immunochromatographic system to detect CD46 according to Example 2 of the present invention;
[0027] Figure 5 This is the immunochromatography system based on MoS2@AuNSs Raman enhanced nanolabels of Example 2 of the present invention, using the test results of serum samples from colorectal cancer patients and healthy people, wherein a is the CD46 immunochromatography detection picture, b is the full signal value of the T line on the immunochromatography test paper, and c is the comparison of the detection signal values of serum samples from colorectal cancer patients and healthy people. DETAILED DESCRIPTION
[0028] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0029] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0030] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0031] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.
[0032] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0033] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.
[0034] The embodiment of the present invention provides a method for preparing a two-dimensional nano-label for CD46 detection, comprising the following steps:
[0035] (1) adding MoS2 nanosheets to PEI solution and ultrasonicating to obtain MoS2@PEI particles;
[0036] (2) Gold nanostars were prepared using colloidal gold nanoparticles as seeds and bovine serum albumin as an inducer;
[0037] (3) mixing the MoS2@PEI particles and the gold nanostars, performing ultrasonic reaction, and centrifuging to obtain MoS2@AuNSs nanosheets;
[0038] (4) The MoS2@AuNSs nanosheet is reacted with 5,5'-dithiobis(2-nitrobenzoic acid) under ultrasonic conditions, and then activated in a carbodiimide solution and an N-hydroxysuccinimide solution, and coupled with a CD-46 antibody to obtain the two-dimensional nanotag.
[0039] In some specific embodiments, in step (1), the concentration of the PEI solution is 0.1-2.5 mg / mL; the ultrasonic conditions are: frequency of 80 kHz, time of 20-50 min.
[0040] In some specific embodiments, in step (2), the particle size of the colloidal gold nanoparticles is 30 nm; and the mass ratio of the colloidal gold nanoparticles to bovine serum albumin is 1:1.
[0041] In some specific embodiments, in step (3), the mass ratio of the MoS2@PEI particles to the gold nanostars is 2:1; the ultrasonic reaction conditions are: frequency of 80 kHz, time of 20 to 40 min; and the centrifugation conditions are: 11000 rpm, 10 min.
[0042] In some specific embodiments, in step (4), the mass ratio of the MoS2@AuNSs nanosheets to 5,5'-dithiobis(2-nitrobenzoic acid) is 10:1; and the ultrasonic conditions are: frequency of 80 kHz and time of 20 to 40 min.
[0043] In some specific embodiments, in step (4), the concentration of the carbodiimide solution is 0.03 M; the concentration of the N-hydroxysuccinimide solution is 0.6 M; the volume ratio of the carbodiimide solution to the N-hydroxysuccinimide solution is 1:1; and the activation time is 10 to 30 min.
[0044] The MoS2@AuNSs two-dimensional Raman-enhanced nanomaterial relies on the spontaneous assembly of the cationic polymer polyethyleneimine (PEI), combined with gold nanostars (AuNSs) with high Raman enhancement efficiency, and coupled with DTNB Raman signal molecules and CD46 antibodies.
[0045] The embodiment of the present invention also provides a two-dimensional nano-tag prepared by the preparation method.
[0046] The embodiment of the present invention also provides the use of the two-dimensional nano-label in preparing a product for detecting CD46.
[0047] The embodiment of the present invention further provides a kit or test strip for detecting CD46, comprising the two-dimensional nano-label.
[0048] The embodiment of the present invention also provides the use of the two-dimensional nano-label in preparing a product for detecting colorectal cancer liver metastasis.
[0049] The present invention first successfully fuses AuNSs and MoS2 through the self-assembly process of PEI to form a composite Raman enhanced structure. On this basis, the DTNB molecule is used as a Raman labeling molecule and attached to the surface of the gold nanostar through a stable Au-S bond. Furthermore, the anti-CD46 antibody is linked to the carboxyl end of DTNB to construct a new high-sensitivity SERS immune label that can be directly used for the direct detection of CD46 in blood samples. The highly sensitive detection method can accurately diagnose colorectal cancer patients and has great application potential in the monitoring of colorectal cancer liver metastasis.
[0050] In the embodiments of the present invention, MoS2 nanosheets were purchased from Xianfeng Nanotechnology Co., Ltd., and CD-46 antibody was purchased from Thermo Fisher Scientific.
[0051] Example 1
[0052] A MoS2@AuNSs@DTNB Raman enhanced two-dimensional nano-label of the present invention comprises a MoS2 two-dimensional nanosheet, a PEI self-assembled layer, a novel gold nanostar (AuNSs) and a DTNB modified and coupled antibody part. The Raman signal molecule DTNB is firmly bound by an Au-S bond, and the terminal carboxyl group of DTNB can be directly coupled to an antibody as a multifunctional two-dimensional SERS immune label. The final sheet diameter of the two-dimensional composite nanomaterial is about 400nm, and it has strong Raman enhancement performance and storage stability.
[0053] The preparation method of the MoS2@AuNSs@DTNB Raman enhanced two-dimensional nano-label in this embodiment is as follows: Figure 1 As shown, the following steps are included:
[0054] (1) 1 mg of negatively charged MoS2 nanosheets of 200-500 nm were added to a 0.8 mg / mL PEI solution and subjected to intense ultrasound (80 KHZ, 30 min) to allow PEI to self-assemble on the surface of the MoS2 nanosheets to form MoS2@PEI particles with a strong positive surface charge;
[0055] (2) Using 2 mL 5 mg / mL 30 nm colloidal gold nanoparticles as seeds, 1 mL 10 mg / mL bovine serum albumin (BSA) as an inducer, sodium citrate and hydroquinone as reducing agents, the new gold nanostars with super SERS enhancement performance were prepared at room temperature for 30 minutes;
[0056] (3) The MoS2@PEI particles (concentration of 1 mg / mL, volume of 1 mL) obtained in step (1) were mixed with 2 mL of 0.25 mg / mL negatively charged gold nanostars prepared in step (2) and subjected to ultrasonic reaction (frequency of 80 KHZ, time of 30 min). In this process, the gold nanostars were uniformly fixed to the surface of the MoS2@PEI particles by electrostatic adsorption. Finally, the mixture was centrifuged at 11000 rpm for 10 min to obtain MoS2@AuNSs nanosheets.
[0057] (4) 10 mL of 1 mg / mL MoS2@AuNSs obtained in step (3) was reacted with 10 μL of 50 μM 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) by ultrasonication (80 KHZ, 35 min) to stabilize the link through the Au-S bond. The terminal carboxyl group was then activated in 0.03 M carbodiimide solution and 0.6 M N-hydroxysuccinimide solution (volume ratio = 1:1) for 15 min. Finally, 10 μg of CD-46 antibody was added for reaction for 2 h to directly couple the CD-46 antibody (capture antibody) as a multifunctional two-dimensional SERS immunolabel MoS2@AuNSs@DTNB.
[0058] Figure 2 The transmission electron microscopy (TEM) images of the MoS2 nanosheets in step (1) of this embodiment and the MoS2@AuNSs nanosheets prepared in step (3) are shown in Figure 1. a is the TEM image of the 400nm MoS2 nanosheets; b is the TEM image of the MoS2@AuNSs nanosheets. As can be seen from the above TEM results, MoS2 presents the shape of two-dimensional nanosheets. The TEM electron microscopy characterization of MoS2@AuNSs shows that AuNSs can be evenly distributed on the surface of molybdenum sulfide. The molybdenum sulfide nanosheets play the role of integrating a large number of AuNSs, so that the product has excellent SERS performance.
[0059] Figure 3 The Raman signal intensity of MoS2@AuNSs prepared in step (3) of this embodiment and MoS2@AuNSs@DTNB prepared in step (4) of this embodiment are characterized. Figure 3 It can be seen that the MoS2@AuNSs prepared by the present invention has super strong Raman enhancement performance and is suitable for the detection of low-concentration targets in human serum samples.
[0060] Example 2
[0061] The MoS2@AuNSs@DTNB Raman-enhanced two-dimensional nano-tag prepared in Example 1 of the present invention has significant Raman enhancement properties, is suitable for use as an efficient SERS marker in two-dimensional SERS technology, and can be effectively combined with an immunochromatographic system to detect target substances. This example uses a CD46 antibody-modified SERS tag combined with an immunochromatographic system to detect different concentrations of CD46 protein in complex samples.
[0062] The MoS2@AuNSs-based SERS immunolabel was put into an untreated blood sample and shaken for 20 minutes. An immunochromatographic test strip (with a CD-46 detection antibody on the detection line) was inserted and the Raman signal at the detection line of the immunochromatographic test strip was read after 10 minutes.
[0063] Figure 4 The figure shows the experimental flow chart of the SERS tag and immunochromatography system of this embodiment for rapid detection of CD46 protein. Figure 5 The results of the two-dimensional SERS tag-based immunochromatographic system of this embodiment for rapid detection of CD46 in human serum samples. Figure 5 Figures a and b are the photos of the immunochromatographic test strips and the Raman spectrometer readings when testing the serum of colorectal cancer patients and healthy people, respectively; Figure 5 Figure c is the t-test result of the Raman signal obtained by detecting CD46 in human serum samples using the immunochromatographic detection system.
[0064] The results showed that the immunochromatographic system using the two-dimensional SERS tag to detect CD46 can accurately distinguish between colorectal cancer patients and healthy people with high specificity when detecting real human serum samples. In addition, it can also be shown that the two-dimensional SERS nanotag has good stability and can complete the detection task in serum samples. The above results show that the immunochromatographic system based on the two-dimensional SERS tag has high sensitivity, good stability, and is suitable for the detection of CD46 in human serum samples, providing a powerful method for clinical diagnosis of colorectal cancer and metastasis monitoring.
[0065] Obviously, the above embodiments of the present invention are merely examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A method for preparing a two-dimensional nanotag for CD46 detection, characterized in that: The following steps are involved: (1) adding MoS2 nanosheets to PEI solution and ultrasonicating to obtain MoS2@PEI particles; (2) Gold nanostars were prepared using colloidal gold nanoparticles as seeds and bovine serum albumin as an inducer; (3) mixing the MoS2@PEI particles and the gold nanostars, performing ultrasonic reaction, and centrifuging to obtain MoS2@AuNSs nanosheets; (4) The MoS2@AuNSs nanosheet is reacted with 5,5'-dithiobis(2-nitrobenzoic acid) under ultrasonic conditions, and then activated in a carbodiimide solution and an N-hydroxysuccinimide solution, and coupled with a CD-46 antibody to obtain the two-dimensional nanotag.
2. The preparation method according to claim 1, characterized in that: In step (1), the concentration of the PEI solution is 0.1-2.5 mg / mL; the ultrasonic conditions are: frequency of 80 kHz, time of 20-50 min.
3. The preparation method according to claim 1, characterized in that: In step (2), the particle size of the colloidal gold nanoparticles is 30 nm; and the mass ratio of the colloidal gold nanoparticles to bovine serum albumin is 1:
1.
4. The preparation method according to claim 1, characterized in that: In step (3), the mass ratio of the MoS2@PEI particles to the gold nanostars is 2:1; the ultrasonic reaction conditions are: frequency of 80 kHz, time of 20 to 40 min; and the centrifugal conditions are: 11000 rpm, 10 min.
5. The preparation method according to claim 1, characterized in that: In step (4), the mass ratio of the MoS2@AuNSs nanosheets to 5,5'-dithiobis(2-nitrobenzoic acid) is 10:1; the ultrasonic conditions are: frequency of 80 kHz, time of 20 to 40 min.
6. The preparation method according to claim 1, characterized in that: In step (4), the concentration of the carbodiimide solution is 0.03 M; the concentration of the N-hydroxysuccinimide solution is 0.6 M; the volume ratio of the carbodiimide solution to the N-hydroxysuccinimide solution is 1:1; and the activation time is 10 to 30 minutes.
7. The two-dimensional nanotag prepared by the preparation method according to any one of claims 1 to 6.
8. Use of the two-dimensional nanotag as claimed in claim 7 in the preparation of a product for detecting CD46.
9. A kit or test strip for detecting CD46, characterized in that: Comprising the two-dimensional nano-tag as claimed in claim 7.
10. Use of the two-dimensional nanotag as claimed in claim 7 in the preparation of a product for detecting colorectal cancer liver metastasis.
